Previous close | 1,221.70 |
Open | 1,220.05 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 1,207.80 - 1,246.10 |
52-week range | 665.75 - 1,292.10 |
Volume | |
Avg. volume | 1,631,358 |
Market cap | 727.483B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 22.97 |
EPS (TTM) | 54.12 |
Earnings date | 10 Aug 2024 - 14 Aug 2024 |
Forward dividend & yield | 4.50 (0.37%) |
Ex-dividend date | 20 Feb 2024 |
1y target est | 953.00 |
Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.